Merrion Pharmaceuticals plc Announces Commencement of Next Stage of Oral Drug Research Collaboration Programme With Novo Nordisk
Advertisement
Merrion Pharmaceuticals today announced the continuation of an oral drug delivery research collaboration programme with Novo Nordisk. This follows on from the completion of several oral feasibility studies combining Merrion's Gastrointestinal permeation Enhancement Technology (GIPET) oral drug delivery technology with Novo Nordisk compounds. In continuation of this collaboration, Merrion will now complete the development of solid dosage forms with GIPET for additional testing.
"We are very pleased to be working on oral versions of Novo Nordisk's compounds. We believe there can be substantial benefit to patients in having oral formulations on these compounds available -- and our GIPET technology has shown the ability to significantly improve the oral delivery of these drugs," John Lynch, Merrion's CEO said.
In more than 20 clinical studies, GIPET technology has been shown to improve the oral absorption of a wide range of drugs, by between 500% and 1500%. Drugs studied ranged from small molecules to small proteins. Merrion currently has four products in development, as well as several collaboration agreements with pharmaceutical partners, using this technology.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
New Consortium Paves the way for Improved Treatment of Hypertension and Associated Vascular Complications
Genzyme: Myozyme Receives Positive Opinion from European Regulatory Committee - Proposed Indication Includes All Patients with Pompe Disease
Liquid salts deliver drugs through the skin with enhanced efficacy and reduced toxicity
New Phase II Data on Millennium's Proteasome Inhibitor Holds Promise for Patients with Refractory Multiple Myeloma
BTG: Study Shows Abiraterone Can Successfully Treat Aggressive, Chemotherapy-Resistant Prostate Cancer
SEQUENOM and National Institutes of Health Expand Relationship for Gene Expression - Agreement Builds on Success of Previous SNP Genotyping Research
Muscle-Targeted Gene Therapy Reverses Rare Muscular Dystrophy in Mice
Study finds 'mad cow disease' in cattle can spread widely in ANS before detectable in CNS
Simple and Fast Method for Radiolabelling Antibodies against Breast Cancer - Using UV light, radiolabelled antibodies can be produced in just 15 minutes
